Zacks Investment Research·Sep 15, 2026
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion StudyIMCR achieves target enrollment in the phase III TEBE-AM study investigating Kimmtrak in previously treated patients with advanced melanoma.
Immunocore's KIMMTRAK franchise is driving accelerating revenue growth (18.3% YoY in 2026Q2) with gross margins above 99%, and operating losses have narrowed dramatically from -$14.9M in 2025Q2 to -$3.0M in 2026Q2, signaling a path to break-even. The company's...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.02-100.0% vs -$0.01 | $116M-22.1% vs $149M |
Q2 2026 May 6, 2026 | $0.25+196.2% vs -$0.26 | $145M-0.3% vs $145M |
Q1 2026 Feb 25, 2026 | -$0.60-114.3% vs -$0.28 | $140M-3.1% vs $144M |
Q4 2025 Nov 6, 2025 | $0.02+105.2% vs -$0.30 | $104M-27.1% vs $142M |
IMCR achieves target enrollment in the phase III TEBE-AM study investigating Kimmtrak in previously treated patients with advanced melanoma.
Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK ® (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as early as end of 2026 (OXFORDSHIRE, England & CONSHOHOCKEN, PA & ROCKVILLE, MD, US, 14 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced the achievement of target patient enrollment (540 patients) in the TEBE-AM clinical trial (NCT05549297). TEBE-AM is a global, randomized, registrational Phase 3 clinical trial evaluating KIMMTRAK (tebentafusp) as monotherapy and in combination with pembrolizumab, versus Investigator's Choice, for the treatment of HLA-A*02:01-positive patients with advanced melanoma whose disease has progressed following prior therapy.
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 1 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in September. Cantor Global Healthcare Conference 2026 Fireside Chat: Thursday, September 10, 2026, at 2:45 p.m.
Benchmark IMCR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Immunocore Holdings plc (IMCR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $31.54 | $1.6B | -59.51 | 20% | -8.88% | -7.12% | — | |
| $115.47 | $9.5B | -31.29 | -16.72% | -285.41% | -21.5% | — | |
| $26.39 | $3.32B | -8.02 | -4.26% | -386.32% | -87.98% | — | |
| $8.40 | $349.8M | -2470.59 | 10.37% | 69.76% | — | — | |
| $3.80 | $241.54M | -3.22 | 0.78% | -8.7% | -31.27% | — | |
| $2.43 | $283.24M | -2.11 | -51.24% | -1941.09% | -65.08% | — |
Immunocore Holdings plc (IMCR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Immunocore Holdings plc (IMCR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
May 27, 2026·SEC
May 6, 2026·SEC
Get notified when IMCR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Immunocore Holdings plc (IMCR) stock FAQ — growth, dividends, profitability & financials explained
Immunocore Holdings plc (IMCR) reported $403.7M in revenue for fiscal year 2025. This represents a 12129% increase from $3.3M in 2013.
Immunocore Holdings plc (IMCR) grew revenue by 20.0% over the past year. This is strong growth.
Immunocore Holdings plc (IMCR) reported a net loss of $9.3M for fiscal year 2025.
Immunocore Holdings plc (IMCR) has a return on equity (ROE) of -7.1%. Negative ROE indicates the company is unprofitable.
Immunocore Holdings plc (IMCR) had negative free cash flow of $62.5M in fiscal year 2025, likely due to heavy capital investments.
